Keyphrases
Hematological Malignancies
75%
Multiple Endocrine Neoplasia Type 2 (MEN2)
70%
ETV6
56%
Spectral Karyotyping
56%
Chromosomal Abnormalities
53%
RET Proto-oncogene
50%
Comparative Genomic Hybridization
50%
T-cell Acute Lymphoblastic Leukemia (T-ALL)
50%
Fluorescence in Situ Hybridization
42%
Genetic Loci
41%
Etoposide
37%
T Cells
35%
Medullary Thyroid Carcinoma
33%
Mitoxantrone
33%
Group Studies
33%
Recurring
32%
Tyrosine Kinase
31%
Fusion Product
31%
Children's Oncology Group
31%
Tumor
30%
Familial Medullary Thyroid Carcinoma
30%
Acute Lymphoblastic Leukemia
30%
Receptor Tyrosine Kinase
30%
Aberrations
28%
CALM-AF10
25%
3p Deletion
25%
Yeast Artificial Chromosome
25%
Hematopathology
25%
Neurofibromatosis Type I
25%
Infantile Fibrosarcoma
25%
Human Chromosomes
25%
Clinical Diagnostic Laboratory
25%
Post-transplant Lymphoproliferative Disorder
25%
Molecular Characterization
25%
Primary Induction Failure
25%
ETV6-NTRK3 Fusion
25%
Myoepithelial Carcinoma
25%
1p Deletion
25%
Karyotype Analysis
25%
Inv(11)(q21q23)
25%
Catalytic Domain
25%
Copy number Variation
25%
Genetic Abnormalities
25%
Meningioma
25%
Relapsed or Refractory Acute Myeloid Leukemia
25%
Genome Resources
25%
Alkylating Agents
25%
Molecular Cytogenetics
25%
Cytogenetic Characterization
25%
Acute Myeloid Leukemia
25%
Biochemistry, Genetics and Molecular Biology
T Cell
100%
Genetics
63%
Cytogenetics
61%
Receptor Tyrosine Kinase
55%
Spectral Karyotyping
55%
Myeloid
50%
ETV6
50%
Allele
48%
Fluorescence in Situ Hybridization
45%
Chromosomal Abnormalities
44%
Gene Locus
41%
Point Mutation
38%
Fusion Transcript
35%
Germ Cell
33%
Karyotype
30%
Morphology
30%
B Cell
30%
Tyrosine Kinase
30%
Exon
28%
KMT2A
25%
Medical Genetics
25%
Chromosomal Disorder
25%
Genotype Phenotype Correlation
25%
RET Proto-Oncogene
25%
Kruppel Like Factor
25%
Progeny
25%
Sex Ratio
25%
TFE3
25%
Karyotyping
25%
Chromosome 22
25%
Enzyme Active Site
25%
Comparative Genomic Hybridization
25%
Missense Mutation
25%
Yeast Artificial Chromosome
25%
Contig
25%
Proto Oncogene
25%
Human Chromosome
25%
Trisomy 9
16%
Carcinogenesis
15%
Chromosome Rearrangement
12%
Centromere
12%
Heterozygosity
12%
Chromosome 11
10%
Chromosome 10
10%
Cyclophosphamide
10%
Reverse Transcription Polymerase Chain Reaction
10%
Epstein Barr Virus
8%
Cell Proliferation
8%
Ligand Binding Domain
8%
Amino Acid Substitution
8%
Medicine and Dentistry
Acute Myeloid Leukemia
56%
Acute Lymphoblastic Leukemia
50%
Neoplasm
50%
T Cell
40%
Acute Myelogenous Leukemia
37%
Etoposide
37%
Kidney Tumour
33%
Pediatrics
31%
Mitoxantrone
31%
Diagnosis
30%
Protein Tyrosine Kinase
30%
Oncology
29%
Diseases
27%
Chromosome Aberration
25%
Thyroid Medullary Carcinoma
25%
Hematologic Malignancy
25%
Hematopathology
25%
Posttransplant Lymphoproliferative Disease
25%
Neurofibromatosis Type I
25%
Proto Oncogene
25%
Cytarabine
25%
Myeloid Malignancy
25%
Alkylating Antineoplastic Agent
25%
Mediator
25%
Fibrosarcoma
25%
Clear Cell Renal Cell Carcinoma
25%
Drug-Resistant Cell Line
25%
Myoepithelial Carcinoma
25%
Kruppel Like Factor
25%
Exon
25%
Comparative Genomic Hybridization
25%
Cell Line
25%
Molecular Diagnosis
25%
Population
25%
Allele
17%
Gene Expression
16%
GAB2
16%
Myeloid Leukemia
15%
Cyclophosphamide
12%
Cytostatic Agent
12%
Drug Resistance
12%
Myelodysplastic Syndrome
12%
Clinical Management
11%
Chromosome 11
11%
Leukemogenesis
11%
B Cell
10%
Trisomy
10%
Multiple Endocrine Neoplasia Type 2a
10%
Lymphoid Leukemia
10%
Chromosome 10
10%